PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8048269

[Liver transplantation: current status].

J P Lerut
View original source ↗Export metadata ↓

Abstract

The liver transplantation has become in hepatology, what kidney- and heart transplantation are for a longer time in nephrology and cardiology. Liver transplantation is a final treatment for an important number of chronic and acute liver diseases as well as for a whole series of metabolic disorders the cause of which is situated in the liver. The important development of the liver transplantation is due to the introduction into clinical practice of the new immunosuppressive drug Cyclosporin, the development of new surgical techniques as well for the procurement as for the transplantation of organs, the improvement and standardization of perioperative care, the introduction of the concept of retransplantation and the use of liver segments for transplantation as well in children as in adults. Every candidate for liver transplantation has to be treated in function of the eventuality of a later transplantation. The introduction of interventional radiological techniques for placing intrahepatic portosystemic shunts and effecting percutaneous dilatation of diffuse bile-duct strictures are important measures which make it possible to carry out later on the transplantation with fewer risks. The poignant lack of organs reduces the progress of transplantation. To make aware of the importance of organ donation not only the public, but also the medical and paramedical staffs is a determining factor in the future of organ transplantation. That lack of organs will be otherwise a good stimulus for inciting the medical staff to consider the indications very strictly; this is especially important in alcoholic cirrhosis, in hepatobiliary carcinoma and in patients with an unfavourable psychosocial context. In future we shall have to watch over the reservation of good organs for the "best" patients. The future financial restrictions in medical matters will also need strict consideration in order to avoid disproportionate costs for transplantation in patients who have poor or even few chances to survive for some time as stated in the "Paris Consensus Conference" of June 1993. All this shows how deeply liver transplantation will influence not only today's Medicine, but also the whole of Society, because it constantly interferes with financial and ethical problems of our modern society.

Explore related subjects

Acute Kidney InjuryBelgiumBiliary Tract NeoplasmsEuropeExtracorporeal CirculationGraft RejectionHumansImmunosuppressive AgentsLiver NeoplasmsLiver TransplantationPostoperative ComplicationsTransplantation, HomologousEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J P Lerut. 1994. [Liver transplantation: current status].. https://pubmed.ncbi.nlm.nih.gov/8048269/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2013

The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics.

Early transplant dysfunction and failure because of immunological and nonimmunological factors still presents a significant clinical problem for transplant recipients. A critical unmet need is the noninvasive detection and prediction of immune injury such that acute injury can be reversed by proactive immunosuppression titration. In this study, we used iTRAQ -based proteomic discovery and targeted ELISA validation to discover and validate candidate urine protein biomarkers from 262 renal allograft recipients with biopsy-confirmed allograft injury. Urine samples were randomly split into a training set of 108 patients and an independent validation set of 154 patients, which comprised the clinical biopsy-confirmed phenotypes of acute rejection (AR) (n = 74), stable graft (STA) (n = 74), chronic allograft injury (CAI) (n = 58), BK virus nephritis (BKVN) (n = 38), nephrotic syndrome (NS) (n = 8), and healthy, normal control (HC) (n = 10). A total of 389 proteins were measured that displayed differential abundances across urine specimens of the injury types (p < 0.05) with a significant finding that SUMO2 (small ubiquitin-related modifier 2) was identified as a "hub" protein for graft injury irrespective of causation. Sixty-nine urine proteins had differences in abundance (p < 0.01) in AR compared with stable graft, of which 12 proteins were up-regulated in AR with a mean fold increase of 2.8. Nine urine proteins were highly specific for AR because of their significant differences (p < 0.01; fold increase >1.5) from all other transplant categories (HLA class II protein HLA-DRB1, KRT14, HIST1H4B, FGG, ACTB, FGB, FGA, KRT7, DPP4). Increased levels of three of these proteins, fibrinogen beta (FGB; p = 0.04), fibrinogen gamma (FGG; p = 0.03), and HLA DRB1 (p = 0.003) were validated by ELISA in AR using an independent sample set. The fibrinogen proteins further segregated AR from BK virus nephritis (FGB p = 0.03, FGG p = 0.02), a finding that supports the utility of monitoring these urinary proteins for the specific and sensitive noninvasive diagnosis of acute renal allograft rejection.

Acute Kidney Injury↗
PubMed2008

Ceftriaxone induced hemolysis complicated by acute renal failure.

Over the last decade, second and third generation cephalosporins have been the most common drugs causing hemolytic anemia (HA). Of these cases, 20% have been attributed to ceftriaxone. The clinical presentation of ceftriaxone-induced HA is usually abrupt with sudden onset of pallor, tachypnea, cardio-respiratory arrest and shock. Acute renal failure (ARF) has been reported in 41% of such cases with a high fatality rate. We report a pediatric patient with ARF complicating ceftriaxone-induced HA who survived. Ceftriaxone is a commonly used drug, and early recognition of HA and institution of supportive care, including dialysis is likely to improve the outcome.

Acute Kidney Injury↗
PubMed2007

Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

Of patients with newly diagnosed multiple myeloma, approximately 10% have dialysis-dependent acute renal failure, with cast nephropathy, caused by monoclonal free light chains (FLC). Of these, 80 to 90% require long-term renal replacement therapy. Early treatment by plasma exchange reduces serum FLC concentrations, but randomized, controlled trials have shown no evidence of renal recovery. This outcome can be explained by the low efficiency of the procedure. A model of FLC production, distribution, and metabolism in patients with myeloma indicated that plasma exchange might remove only 25% of the total amount during a 3-wk period. For increasing FLC removal, extended hemodialysis with a protein-leaking dialyzer was used. In vitro studies indicated that the Gambro HCO 1100 dialyzer was the most efficient of seven tested. Model calculations suggested that it might remove 90% of FLC during 3 wk. This dialyzer then was evaluated in eight patients with myeloma and renal failure. Serum FLC reduced by 35 to 70% within 2 hr, but reduction rates slowed as extravascular re-equilibration occurred. FLC concentrations rebounded on successive days unless chemotherapy was effective. Five additional patients with acute renal failure that was caused by cast nephropathy then were treated aggressively, and three became dialysis independent. A total of 1.7 kg of FLC was removed from one patient during 6 wk. Extended hemodialysis with the Gambro HCO 1100 dialyzer allowed continuous, safe removal of FLC in large amounts. Proof of clinical value now will require larger studies.

Acute Kidney Injury↗